The purpose of this trail is to evaluate the performance of Genetron lung cancer panel in non-small cell lung cancer patients using semiconductor sequencing method.

开始日期2018-08-30

申办/合作机构

河南省肿瘤医院

[+3]

100 项与北京泛生子基因科技有限公司相关的临床结果

登录后查看更多信息

0 项与北京泛生子基因科技有限公司相关的专利（医药）

登录后查看更多信息

项与北京泛生子基因科技有限公司相关的文献（医药）

2025-12-01·Therapeutic Advances in Medical Oncology

Unraveling the alterations and biomarkers in the tumor microenvironment in lung adenocarcinoma metastases and their indications for therapeutic response and prognosis

Review

作者: Guan, Chao ; Zhou, Zhicheng ; Yu, Li ; Song, Lele ; Zhao, Jungang ; Li, Xiangmin ; Du, Zhenguang ; Zeng, Xiaoshan

Lymph nodes, brain, bone, and liver are recognized as the four most common metastatic sites for lung adenocarcinoma (LUAD). Metastasis to these locations exhibits some common features, such as immune suppression, and distinct tumor microenvironment (TME) heterogeneity involving differentiation of immune cells, impacting treatment efficacy and prognosis. Lymph node metastases are characterized by immune suppression with exhausted CD8+ T cells, expanded regulated T cell (Tregs), M2-polarized macrophages, and high programmed death ligand-1 (PD-L1) expression. Brain metastases display an “immune desert” phenotype due to blood–brain barrier constraints, reduced T-cell infiltration, and microglia-mediated immunosuppression. Bone metastases involve osteoclast activation, RANKL/OPG pathway dysregulation, and metabolic reprogramming, while liver metastases show Kupffer cell-driven PD-L1/ programmed death 1(PD-1) axis suppression and elevated Treg infiltration. Key biomarkers across all types of metastases include PD-L1, cytokine profiles, immune cell ratios, and metabolic markers. Therapeutic strategies focus on combination therapies such as immune checkpoint inhibitors (ICIs) with metabolic modulators, localized drug delivery, and biomarker-guided approaches. Challenges in this field encompass spatial heterogeneity, dynamic TME evolution, and clinical translation barriers. Future research directions highlight spatial transcriptomics, microbiome interactions, and organoid models to optimize personalized immunotherapy. This article aims to provide a comprehensive review of regarding TME alterations across these four main metastatic locations of LUAD. It will also discuss relevant TME biomarkers and their clinical significance on therapeutic response and prognosis. We expect this article to serve as a source of evidence and inspiration for the future development of treatment strategies based on LUAD TME.

2023-01-01·Clinical lung cancer

A Novel PRKAR1A::MET Fusion Dramatic Response to Crizotinib in a Patient with Unresectable Lung Cancer

作者: Zhang, Yanxiang ; Yang, Yang ; Zhao, Dandan ; Li, Xiaoli ; Ma, Tonghui

This report demonstrated a significant clin. benefit from first-line treatment of crizotinib in a patient with unresectable lung cancer with novel PRKAR1A::MET gene fusion.After disease progress resulted from discontinued therapy, the patient still achieved clin. benefit from second-line monotherapy of crizotinib.This finding provided insight to perform the clin. trials to assess the efficacy and rationale of first-line or second line treatment to patients with unresectable lung cancer carrying MET fusion.

2023-01-01·Frontiers in oncology

Long-term partial response in a patient with liver metastasis of primary adrenocortical carcinoma with adjuvant mitotane plus transcatheter arterial chemoembolization and microwave ablation: a case report.

作者: Ji, Zhigang ; Wu, Zoey ; Wei, Lihui ; Deng, Jianhua ; Fan, Qihuang

Adrenocortical carcinoma (ACC) is a rare, heterogeneous, and aggressive malignancy with a generally poor prognosis. Surgical resection is the optimal treatment plan. After surgery, both mitotane treatment or the etoposide-doxorubicin-cisplatin (EDP) protocol plus mitotane chemotherapy have a certain effect, but there is still an extremely high possibility of recurrence and metastasis. The liver is one of the most common metastatic targets. Therefore, techniques such as transcatheter arterial chemoembolization (TACE) and microwave ablation (MWA) for liver tumors can be attempted in a specific group of patients. We present the case of a 44-year-old female patient with primary ACC, who was diagnosed with liver metastasis 6 years after resection. During mitotane treatment, we performed four courses of TACE and two MWA procedures in accordance with her clinical condition. The patient has maintained the partial response status and has currently returned to normal life to date. This case illustrates the value of the practical application of mitotane plus TACE and MWA treatment.

项与北京泛生子基因科技有限公司相关的新闻（医药）

2024-03-28

·PRNewswire

World Molecular Diagnostics for Cancer Markets, 2023-2024 and 2027 with Profiles of Over 120 Companies

DUBLIN, March 28, 2024 /PRNewswire/ -- The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Exciting technical developments especially in companion diagnostics, hold the promise of a dynamic, growing and evolving world market where single laboratories serve a global patient base. The report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities' growth. Again, assistance in using the information is normally provided without additional charges. After a pandemic interruption the market for Cancer Molecular Diagnostics is back on the growth path. And growth is accelerating in every segment. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. Over 120 companies are profiled. A range of dynamic trends are pushing market growth and company valuations. Key Market Trends Personalized medicine Pharmacogenomics Liquid biopsy Minimal residual disease testing Emergence of new economies with large markets Physician diagnostics being displaced by new intelligent diagnostic tests Key Topics Covered: 1 Market Guides 1.1 Cancer MDx - Strategic Situation Analysis 1.2 Guide for Executives, Marketing, and Business Development Staff 1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 What are Molecular Diagnostics? 2.2 The Diagnostics Revolution 2.3 Market Definition 2.3.1 Revenue Market Size 2.4 Methodology 2.4.1 Methodology 2.4.2 Sources 2.4.3 Authors 2.5 Perspective: Healthcare and the IVD Industry 2.5.1 Global Healthcare Spending 2.5.2 Spending on Diagnostics 2.5.3 Important Role of Insurance for Diagnostics 3 Market Overview 3.1 Market Segments 3.1.1 Traditional Market Segmentation 3.1.2 Laboratory Focus and Segmentation 3.2 Industry Structure 3.2.1 Hospital Testing Share 3.2.2 Economies of Scale 3.2.3 Physician Office Labs 3.2.4 Physicians and POCT 4 Market Trends 4.1 Factors Driving Growth 4.1.1 New Diagnostics Create New Markets 4.1.2 New Roles for Diagnostics 4.1.3 The Aging Effect 4.1.4 Expanding the Pharmaceutical Toolbox 4.1.5 Regulatory Retreat 4.2 Factors Limiting Growth 4.2.1 Falling Prices 4.2.2 Lower Costs 4.2.3 Wellness has a Downside 4.3 Instrumentation, Automation and Diagnostic Trends 4.3.1 Traditional Automation and Centralization 4.3.2 The New Automation, Decentralization and Point Of Care 4.3.3 Instruments Key to Market Share 4.3.4 Bioinformatics Plays a Role 4.3.5 PCR Takes Command 4.3.6 Next Generation Sequencing Fuels a Revolution 4.3.7 NGS Impact on Pricing 4.3.8 Whole Genome Sequencing, A Brave New World 4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 4.3.10 Shifting Role of Diagnostics 4.3.11 Multiplexing and Foundation One 4.3.12 Pharmacogenomics Technology 4.3.13 Gene Editing and Gene Therapy 5 Molecular Diagnostics Recent Developments 5.1 Recent Developments - Importance and How to Use This Section 5.1.1 Importance of These Developments 5.1.2 How to Use This Section 5.2 Grail Cancer Test Faces New Clinical Questions 5.3 Freenome Acquires Cancer Dx Firm Oncimmune 5.4 Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology 5.5 Ultima Genomics, Genome Insight Partner on WGS for Cancer Patients 5.6 Digital Pathology Meets Cancer Sequencing 5.7 Exact Sciences Preps Expanded Oncology Portfolio 5.8 Qiagen Details Oncology Plans for Digital PCR Platform 5.9 Sema4 Exiting Reproductive Health Screening 5.10 Thermo Fisher Introduces Cancer Profiling Assay 5.11 Genomic Test IDs Cysts Likely to Progress to Cancer 5.12 Naveris to Commercialize Virus-Related Cancer Tests 5.13 Larger Liquid Biopsy Panels Loom 5.14 Halo Diagnostics to Offer Genomic Profiling Tests 5.15 BillionToOne Raises $125M 5.16 Local Cancer Genomic Profiling Options Grow 5.17 German MDx Firm Mainz Biomed Raises $10M in IPO 5.18 Guardant Health Q3 Revenues Up 27 Percent 5.19 BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection 5.20 Nucleix to Invest in Early-Stage Lung Cancer Dx 5.21 Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics 5.22 Grail Gets Approval for Galleri Multicancer Test 5.23 Finnish Firms to Form Point-of-Care Testing Firm 5.24 Datar Cancer Genetics Expands to Dx and Screening 5.25 HTG Molecular Diagnostics: HTG Transcriptome Panel 5.26 PacBio's Omniome Acquisition Shortens Path to Clinical 5.27 Invitae to Acquire Genosity for $200M 5.28 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test 5.29 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience 5.30 Natera Revenues Grow 35 Percent 5.31 AnchorDx Closes $40M Financing Round 5.32 Exact Sciences Strategy for End-to-End Cancer Testing 5.33 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch 6 Profiles of Key MDx Companies 6.1 10x Genomics, Inc. 6.2 Abbott Laboratories 6.3 AccuraGen Inc. 6.4 Adaptive Biotechnologies 6.5 Aethlon Medical 6.6 Agilent/Dako 6.7 Anchor Dx 6.8 ANGLE plc 6.9 ARUP Laboratories 6.10 AVIVA Systems Biology 6.11 Baylor Miraca Genetics Laboratories 6.12 Beckman Coulter Diagnostics 6.13 Becton, Dickinson and Company 6.14 BGI Genomics Co. Ltd 6.15 BillionToOne 6.16 Bioarray Genetics 6.17 Biocartis 6.18 Biocept, Inc. 6.19 Biodesix Inc. 6.20 BioFluidica 6.21 BioGenex 6.22 BioIVT 6.23 Biolidics Ltd 6.24 bioMerieux Diagnostics 6.25 Bioneer Corporation 6.26 Bio-Rad Laboratories, Inc 6.27 Bio-Reference Laboratories 6.28 Bio-Techne 6.29 Bioview 6.30 Bolidics 6.31 Boreal Genomics 6.32 Bristol-Myers Squibb 6.33 Burning Rock 6.34 Cardiff Oncology 6.35 Caris Molecular Diagnostics 6.36 Castle Biosciences, Inc. 6.37 Celemics 6.38 CellCarta 6.39 CellMax Life 6.40 Cepheid (Danaher) 6.41 Charles River Laboratories 6.42 Circulogene 6.43 Cizzle Biotech 6.44 Clinical Genomics 6.45 Cytolumina Technologies Corp. 6.46 Datar Cancer Genetics Limited 6.47 Diagnologix LLC 6.48 Diasorin S.p.A. 6.49 Dxcover 6.50 Enzo Biochem 6.51 Epic Sciences 6.52 Epigenomics AG 6.53 Eurofins Scientific 6.54 Exact Sciences 6.55 Fabric Genomics 6.56 Fluxion Biosciences 6.57 Freenome 6.58 FUJIFILM Wako Diagnostics 6.59 Fulgent Genetics 6.60 Fyr Diagnostics 6.61 GeneFirst Ltd. 6.62 Genetron Holdings 6.63 GenomOncology 6.64 GILUPI Nanomedizin 6.65 Guardant Health 6.66 HansaBiomed 6.67 HeiScreen 6.68 Helomics 6.69 HTG Molecular Diagnostics 6.70 iCellate 6.71 ICON PLC 6.72 Illumina 6.73 Incell Dx 6.74 Inivata 6.75 INOVIQ 6.76 Integrated Diagnostics 6.77 Invitae Corporation 6.78 Invivogen 6.79 Invivoscribe 6.80 Janssen Diagnostics 6.81 Lunglife AI Inc 6.82 MDNA Life SCIENCES, Inc. 6.83 MDx Health 6.84 Menarini Silicon Biosystems 6.85 Mesa Laboratories, Inc. 6.86 Millipore Sigma 6.87 Miltenyi Biotec 6.88 miR Scientific 6.89 Myriad Genetics/Myriad RBM 6.90 NantHealth, Inc. 6.91 Natera 6.92 NeoGenomics 6.93 NGeneBio 6.94 Novogene Bioinformatics Technology Co., Ltd. 6.95 Oncocyte 6.96 OncoDNA 6.97 Ortho Clinical Diagnostics 6.98 Oxford Nanopore Technologies 6.99 PamGene 6.100 Panagene 6.101 Perkin Elmer 6.102 Personal Genome Diagnostics 6.103 Personalis 6.104 Precipio 6.105 Precision Medicine Group 6.106 PrecisionMed 6.107 Predicine 6.108 Promega 6.109 Qiagen 6.110 Rarecells SAS 6.111 RareCyte 6.112 Roche Molecular Diagnostics 6.113 Screencell 6.114 Sema4 Holdings 6.115 Sense Biodetection 6.116 Siemens Healthineers 6.117 simfo GmbH 6.118 Singlera Genomics Inc. 6.119 Singulomics 6.120 SkylineDx 6.121 Standard BioTools 6.122 Sysmex Inostics 6.123 Tempus Labs, Inc. 6.124 Thermo Fisher Scientific Inc. 6.125 Todos Medical 6.126 Variantyx 6.127 Veracyte 6.128 Volition 6.129 Vortex Biosciences 6.130 Vyant Bio 6.131 Zhejiang Orient Gene Biotech For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

并购IPO

2023-12-12

·今日头条

【会议倒计时1天】实体瘤MRD精准诊疗论坛即将盛大开幕，群英荟萃，引领精准诊疗新篇章！

信使RNA

2023-12-07

·今日头条

【日程揭晓】实体瘤MRD精准诊疗论坛即将盛大开幕，群英荟萃，引领精准诊疗新篇章！

论坛背景随着精准医学和分子诊断技术的发展，对微小残留病灶（Minimal Residual Disease,MRD）的检测已成为一种重要的临床需求。随着大量临床试验的推进，MRD检测近年从血液肿瘤慢慢扩展到实体肿瘤中，在多种实体瘤中均有价值。但同时实体瘤MRD检测也面临着技术难度大、灵敏度要求高等挑战，需要不断探索和创新。为了探索实体瘤MRD检测技术的创新，促进其在临床诊断和新药研发领域的应用突破，上海多家医药健康产业协会联合主办，泛生子和长三角一体化基因检测联盟协办，张江生物医药基地支持的 “实体瘤MRD精准诊疗论坛” 将于 2023年12月13日13:00-18:00 在上海张江举办。论坛将邀请创新药企大咖和研发团队负责人、临床及科研PI、创新生物技术专家等，共同探讨实体瘤MRD精准诊疗的最新应用进展、临床实践和前沿趋势。时间地点 2023年12月13日13:00-18:00 上海·张江组织架构主办单位：上海现代服务业联合会大健康服务专业委员会上海市浦东新区生物产业行业协会转化医学网新源转化医学中心协办单位：北京泛生子基因科技有限公司长三角一体化基因检测联盟支持单位：上海张江生物医药基地开发有限公司会议日程开幕式致辞王思振 | 泛生子联合创始人、董事长兼CEO 殷晓璐 | 阿斯利康全球研发精准医学部(中国区)负责人探微索道：实体瘤MRD检测技术再定义主持人：张景宇 | 罗氏全球药品开发中国转化医学负责人 13:40-14:10 主题报告基于ctDNA的最小残留病灶检测在实体瘤药物研发中的应用覃灏 | 阿斯利康精准医学分子诊断负责人 14:10-14:40 主题报告肿瘤液态活检解决方案焦宇辰 | 泛生子首席技术官 14:40-14:50 嘉宾互动【Q&A】 14:50-15:30 圆桌对话 MRD对于肿瘤创新药物研发的助力及未来发展影响主持人：胡云富 | 泛生子首席医疗官讨论嘉宾：张景宇 | 罗氏全球药品开发中国转化医学负责人殷晓璐 | 阿斯利康全球研发精准医学部（中国区）负责人陈椎 | 和誉生物联合创始人兼CSO 青敏 | 强生精准医疗诊断科学总监焦宇辰 | 泛生子首席技术官见微知著: 实体瘤MRD临床应用新进展主持人：殷晓璐 | 阿斯利康全球研发精准医学部(中国区)负责人 15:30-16:00 主题报告 MRD在肺癌诊疗中应用的现状及进展李子明 | 上海市胸科医院肺部肿瘤临床医学中心副主任 16:00-16:30 主题报告基于循环肿瘤DNA的MRD评估在肠癌中的应用进展彭俊杰 | 复旦大学附属肿瘤医院大肠外科主任医师 16:30-17:00 主题报告 MRD在泛癌种诊疗中应用的现状及进展赵翌 | 大连医科大学附属第一医院肿瘤科主任医师 17:00-17:40 圆桌对话 MRD从科研到临床落地的关键挑战主持人：殷晓璐 | 阿斯利康全球研发精准医学部（中国区）负责人讨论嘉宾：李子明 | 上海市胸科医院肺部肿瘤临床医学中心副主任彭俊杰 | 复旦大学附属肿瘤医院大肠外科主任医师赵翌 | 大连医科大学附属第一医院肿瘤科主任医师陆虹旻 | 上海交通大学医学院附属仁济医院肿瘤科副主任医师 18:00-20:00 晚宴部分嘉宾（排名不分先后，持续更新中...）彭俊杰教授复旦大学附属肿瘤医院大肠外科主任医师，大肠综合治疗科副主任赵翌教授大连医科大学附属第一医院肿瘤科主任医师、教授、博士生导师李子明教授上海市胸科医院肺部肿瘤临床医学中心副主任、副主任医师陆虹旻教授上海交通大学医学院附属仁济医院肿瘤科副主任医师、肿瘤免疫学博士、日间化疗中心主任殷晓璐博士阿斯利康全球研发精准医学部（中国区）负责人张景宇博士罗氏全球药品开发中国转化医学负责人陈椎博士和誉生物联合创始人兼 CSO 覃灏博士阿斯利康精准医学分子诊断负责人青敏博士强生精准医疗诊断科学总监王思振泛生子联合创始人、董事长兼CEO 胡云富博士泛生子首席医疗官焦宇辰博士泛生子首席技术官论坛亮点聚焦前沿，巅峰对话：论坛邀请多位在领域拥有丰富经验的临床专家、药企研发人员、转化医学负责人等富有洞见和影响力的意见领袖，分享实体瘤MRD检测技术再定义及临床新应用等前沿热点。专业严谨，注重互动：会务组将进行严格的筛选，以确保参会嘉宾均为肿瘤精准诊疗相关领域的资深人士。论坛设置主题报告、圆桌对话、嘉宾问答等多个环节，鼓励与会者积极互动交流，共同推动实体瘤MRD精准诊疗技术的研发探索。更多惊喜亮点，敬请期待！参会报名名额有限，报满即止！联系我们联系人：李老师手机：180 1971 3070（微信同号）邮箱：liminji@360zhyx.com

信使RNA

100 项与北京泛生子基因科技有限公司相关的药物交易

登录后查看更多信息

100 项与北京泛生子基因科技有限公司相关的转化医学

登录后查看更多信息